These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 9098663)

  • 1. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.
    Davis R; Whittington R; Bryson HM
    Drugs; 1997 Apr; 53(4):608-36. PubMed ID: 9098663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nefazodone: a new antidepressant.
    Ellingrod VL; Perry PJ
    Am J Health Syst Pharm; 1995 Dec; 52(24):2799-812. PubMed ID: 8748566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and safety: essentials in antidepressant pharmacotherapy.
    Lader MH
    J Clin Psychiatry; 1996; 57 Suppl 2():39-44. PubMed ID: 8626362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials.
    Sussman N; Ginsberg DL; Bikoff J
    J Clin Psychiatry; 2001 Apr; 62(4):256-60. PubMed ID: 11379839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nefazodone: its place among antidepressants.
    Cyr M; Brown CS
    Ann Pharmacother; 1996 Sep; 30(9):1006-12. PubMed ID: 8876863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of antidepressants: focus on nefazodone.
    DeVane CL; Grothe DR; Smith SL
    J Clin Psychiatry; 2002; 63 Suppl 1():10-7. PubMed ID: 11890560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants.
    Augustin BG; Cold JA; Jann MW
    Pharmacotherapy; 1997; 17(3):511-30. PubMed ID: 9165554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
    Fawcett J; Marcus RN; Anton SF; O'Brien K; Schwiderski U
    J Clin Psychiatry; 1995; 56 Suppl 6():37-42. PubMed ID: 7649972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    Gunasekara NS; Noble S; Benfield P
    Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
    Cohn CK; Robinson DS; Roberts DL; Schwiderski UE; O'Brien K; Ieni JR
    J Clin Psychiatry; 1996; 57 Suppl 2():15-8. PubMed ID: 8626358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
    Davis R; Wilde MI
    CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety profile of nefazodone.
    Robinson DS; Roberts DL; Smith JM; Stringfellow JC; Kaplita SB; Seminara JA; Marcus RN
    J Clin Psychiatry; 1996; 57 Suppl 2():31-8. PubMed ID: 8626361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone.
    Elliott AJ; Russo J; Bergam K; Claypoole K; Uldall KK; Roy-Byrne PP
    J Clin Psychiatry; 1999 Apr; 60(4):226-31. PubMed ID: 10221282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy in long-term treatment of depression.
    Montgomery SA
    J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
    Horst WD; Preskorn SH
    J Affect Disord; 1998 Dec; 51(3):237-54. PubMed ID: 10333980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Milnacipran. A review of its use in depression.
    Spencer CM; Wilde MI
    Drugs; 1998 Sep; 56(3):405-27. PubMed ID: 9777315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of nefazodone.
    Greene DS; Barbhaiya RH
    Clin Pharmacokinet; 1997 Oct; 33(4):260-75. PubMed ID: 9342502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nefazodone: aspects of efficacy.
    Rickels K; Robinson DS; Schweizer E; Marcus RN; Roberts DL
    J Clin Psychiatry; 1995; 56 Suppl 6():43-6. PubMed ID: 7649973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic dose range of nefazodone in the treatment of major depression.
    Robinson DS; Marcus RN; Archibald DG; Hardy SA
    J Clin Psychiatry; 1996; 57 Suppl 2():6-9. PubMed ID: 8626365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.